Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02739984 · ClinicalTrials.gov registry record · Phase 3

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

A Phase 3 study of Type 2 Diabetes and Hypercholesterolemia, sponsored by Amgen.

Completed
Registry status
Phase 3
Development phase
424
Enrollment target
20
Study locations

NCT02739984 is a Phase 3 study of Type 2 Diabetes and Hypercholesterolemia that has completed, run by Amgen. The registered enrollment target is 424 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02739984, a Phase 3 study of Type 2 Diabetes and Hypercholesterolemia, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 3
Development phase
424 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.

Conditions Studied

Type 2 Diabetes Hypercholesterolemia Mixed Dyslipidemia

Interventions

  • BIOLOGICAL Evolocumab
  • DRUG Placebo to Evolocumab

Study Locations (20)

Florida

  • Research Site - Boca Raton
  • Research Site - Coral Gables
  • Research Site - Daytona Beach
  • Research Site - Fleming Island
  • Research Site - Hollywood
  • Research Site - Inverness
  • Research Site - Jacksonville
  • Research Site - Miami

California

  • Research Site - Lomita
  • Research Site - Los Angeles
  • Research Site - Roseville
  • Research Site - San Ramon
  • Research Site - Spring Valley
  • Research Site - Tarzana
  • Research Site - Walnut Creek

Colorado

  • Research Site - Denver
  • Research Site - Lakewood

Alabama

  • Research Site - Tuscumbia

Arizona

  • Research Site - Phoenix

Delaware

  • Research Site - Wilmington

Trial Details

FieldValue
Enrollment Target 424 participants
Start Date 2016-05-17
Est. Completion 2017-08-03
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02739984

The ClinicalTrials.gov registry entry for NCT02739984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (61% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Evolocumab is the first listed.

NCT02739984 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02739984 about?

NCT02739984 is a clinical study titled "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia". The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral do...

What is the current status of trial NCT02739984?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2016-05-17. Estimated completion is 2017-08-03.

What conditions does trial NCT02739984 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Hypercholesterolemia, Mixed Dyslipidemia.

What interventions are being tested in trial NCT02739984?

The interventions under investigation include: Evolocumab (BIOLOGICAL), Placebo to Evolocumab (DRUG).

Who is sponsoring clinical trial NCT02739984?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02739984 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Hypercholesterolemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.